New #JITC article: AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors Monash Health https://bit.ly/46YEIsE
Journal for ImmunoTherapy of Cancer’s Post
More Relevant Posts
-
New #JITC article: Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial Peking University https://bit.ly/4dHsyqJ
To view or add a comment, sign in
-
New #JITC article: Cancer cell-specific PD-L1 expression is a predictor of poor outcome in patients with locally advanced oral cavity squamous cell carcinoma https://bit.ly/3XS6vYR Peter Mac Cancer Research Laboratories
To view or add a comment, sign in
-
It was great to see Ignacio Melero and Alexandra Snyder, MD together at the Society for Immunotherapy of Cancer (SITC) IO Drug Development Summit in Boston! They make quite the team as #JITC Immunotherapy Biomarkers Section Editors. 🤩 Take a look at the scope of their section to see if your research would catch their eyes in JITC: https://lnkd.in/gKChK7-H #Immunotherapy #Biomarkers #Manuscript #ScientificPublishing
To view or add a comment, sign in
-
Check out the recent #JITC Editor Pick from Cesare Di Nitto et al, "An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade" https://bit.ly/3ZLg4uU
To view or add a comment, sign in
-
Meet the Author: Charlotte L. B. M. Korst, a PhD candidate from Amsterdam UMC, is 1st author of “Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in Multiple Myeloma,” recently published in #JITC! Charlotte Korst is currently a fifth year PhD candidate in the Department of Hematology in the Amsterdam UMC. Before starting her PhD, she worked as a resident not-in-training in the Internal Medicine & Hematology department. She expects to complete her PhD next year. She finds it inspiring that research conducted in the lab can lead to new treatments strategies for patients within years. The PhD journey has given her the opportunity to gain more insight into both translational and clinical research and she hopes to make a meaningful contribution to the field. Her PhD focuses on #immunotherapy for multiple myeloma, spanning clinical & preclinical research. She finds the combination of patient care + lab work highly valuable. Treatment for #multiplemyeloma is rapidly evolving, so she learns about new treatments in the lab & the clinic. After finishing her PhD, she plans to apply for the specialty training in Internal Medicine. Her goal is to become a #hematologist. She finds publishing in JITC valuable because “JITC provides a comprehensive overview of the newest developments in immunotherapies for cancer. This allows researchers to expand their perspectives beyond their specialty. This will advance the entire field of immunotherapy.” Outside of research, she enjoys reading literature, visiting art exhibitions, and studying the French language and culture. Read her recent work here: https://lnkd.in/gtCnUuMX
To view or add a comment, sign in
-
New #JITC short report: Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy https://bit.ly/3ZG7TQG
To view or add a comment, sign in
-
New #JITC article: MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors https://bit.ly/4dfGNTt
To view or add a comment, sign in
-
In honor of #PeerReviewWeek - Thank you to the many #JITC reviewers who support the advancement of cancer immunotherapy! 👏 ⭐ https://bit.ly/47nEHQk
To view or add a comment, sign in
-
New #JITC article: S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling DKFZ German Cancer Research Center https://bit.ly/3XEA0y9
To view or add a comment, sign in
2,493 followers